SCHEDULE: Pyxis Oncology: Biotechnology Value Funds Disclose Stake

Several Biotechnology Value Funds and Mark N. Lampert have jointly filed a Schedule 13G, disclosing beneficial ownership of Pyxis Oncology, Inc. common stock and warrants.

Summary

• This filing is a Schedule 13G, indicating that the reporting persons are passive investors and not seeking to control the company.
• The reporting persons include various Biotechnology Value Funds (L.P., II L.P., Trading Fund OS LP, Partners OS Ltd., Partners L.P./IL, Inc./IL), their associated general partners (BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC), and Mark N. Lampert.
• As of July 10, 2026, the reporting persons collectively beneficially owned 7,840,062 Warrants, exercisable for 7,840,062 shares of Pyxis Oncology's Common Stock.
• These Warrants have an exercise price of $3.289 per share and are exercisable on or after the earlier of the public disclosure of clinical data from the micvotabart pelidotin (MICVO) Phase 1 study or October 1, 2026, expiring on July 2, 2029.
• A 9.99% beneficial ownership limit applies to the exercise of these Warrants.
• Specific holdings as of July 10, 2026, include: BVF (4,611,887 shares, including 496,840 underlying warrants), BVF2 (3,083,847 shares, excluding underlying warrants), and Trading Fund OS (518,280 shares, excluding underlying warrants).
• Various entities and Mr. Lampert may be deemed to beneficially own shares held by other reporting entities due to their roles as general partners, members, or investment managers.
• The total percentage of class represented by the aggregate beneficial ownership of Partners, BVF Inc., and Mr. Lampert is approximately 9.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership and warrant holdings, without new operational or financial performance data.

Positives

• The filing indicates a significant investment by established biotechnology-focused funds, suggesting confidence in Pyxis Oncology's potential.
• The reporting persons are classified as passive investors, which typically implies they are not seeking to exert control or disrupt current management.
• The Warrants provide a potential upside for the reporting persons if the company's stock price increases and clinical milestones are met.

Negatives

• The reporting persons hold Warrants with a specific exercise price ($3.289), which means they will only profit if the stock price significantly exceeds this level.
• The 9.99% beneficial ownership limit on warrant exercise restricts the immediate conversion of all held warrants into shares, capping immediate potential ownership.
• The exercise of warrants is contingent on the disclosure of clinical data from the MICVO Phase 1 study, introducing uncertainty regarding the timing of potential share acquisition.

Risks

• The exercise of Warrants is subject to a 9.99% beneficial ownership limit, potentially restricting the ability to acquire a larger stake.
• The exercise of Warrants is contingent on the disclosure of clinical data from the MICVO Phase 1 study, which may not meet expectations or could be delayed.
• The Warrants expire on July 2, 2029, creating a time-bound opportunity for exercise and potential profit.

Future Outlook

The exercise of Warrants is contingent upon the disclosure of clinical data from Pyxis Oncology's micvotabart pelidotin (MICVO) Phase 1 monotherapy study and has an expiration date of July 2, 2029. A 9.99% ownership cap limits the immediate exercise of all underlying shares.

Industry Context

StockSavvy.ai notes that this filing reflects typical activity for specialized biotechnology investment funds that acquire warrants and other equity instruments in early-to-mid-stage biotech companies, often tied to clinical development milestones.

Stakeholder Impact

• Shareholders: The filing confirms significant passive investment by specialized funds, which could be viewed positively as a sign of institutional interest, but does not directly impact current operations or immediate share price without warrant exercise.
• Creditors: No direct impact on creditors is indicated by this filing.
• Employees: No direct impact on employees is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.

Next Steps

• Monitoring the disclosure of clinical data from the MICVO Phase 1 study.
• Observing potential exercise of Warrants by the reporting persons.
• Tracking Pyxis Oncology's stock performance relative to the warrant exercise price.

Key Dates

Keywords

Pyxis Oncology, Schedule 13G, Biotechnology Value Fund, Mark N. Lampert, Warrants, Beneficial Ownership, SEC Filing, Common Stock, Investment